fluoxetine has been researched along with Hemorrhagic Stroke in 2 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Hemorrhagic Stroke: Stroke due to rupture of a weakened blood vessel in the brain (e.g., CEREBRAL HEMISPHERES; CEREBELLUM; SUBARACHNOID SPACE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures." | 9.41 | Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration. ( Almeida, OP; Anderson, CS; Billot, L; Dennis, MS; Etherton-Beer, C; Flicker, L; Ford, AH; Gommans, J; Hackett, ML; Hankey, GJ; Jan, S; Lundström, E; Lung, T; Mead, GE; Sunnerhagen, KS; Thang-Nguyen, H; Yi, Q, 2021) |
| "The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures." | 5.41 | Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration. ( Almeida, OP; Anderson, CS; Billot, L; Dennis, MS; Etherton-Beer, C; Flicker, L; Ford, AH; Gommans, J; Hackett, ML; Hankey, GJ; Jan, S; Lundström, E; Lung, T; Mead, GE; Sunnerhagen, KS; Thang-Nguyen, H; Yi, Q, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marquez-Romero, JM | 1 |
| Reyes-Martínez, M | 1 |
| Huerta-Franco, MR | 1 |
| Ruiz-Franco, A | 1 |
| Silos, H | 1 |
| Arauz, A | 1 |
| Hankey, GJ | 1 |
| Hackett, ML | 1 |
| Almeida, OP | 1 |
| Flicker, L | 1 |
| Mead, GE | 1 |
| Dennis, MS | 1 |
| Etherton-Beer, C | 1 |
| Ford, AH | 1 |
| Billot, L | 1 |
| Jan, S | 1 |
| Lung, T | 1 |
| Lundström, E | 1 |
| Sunnerhagen, KS | 1 |
| Anderson, CS | 1 |
| Thang-Nguyen, H | 1 |
| Gommans, J | 1 |
| Yi, Q | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage (FMRICH): a Randomised Placebo-controlled Trial[NCT01737541] | Phase 3 | 32 participants (Actual) | Interventional | 2012-11-30 | Terminated (stopped due to Study recruitment was suspended due to lack of funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for fluoxetine and Hemorrhagic Stroke
| Article | Year |
|---|---|
Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH trial.
Topics: Aged; Basal Ganglia Hemorrhage; Double-Blind Method; Female; Fluoxetine; Hemorrhagic Stroke; Humans; | 2020 |
Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration.
Topics: Accidental Falls; Affect; Aged; Cognition; Double-Blind Method; Fatigue; Female; Fluoxetine; Fractur | 2021 |